Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis

Company Overview

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development. In the biosimilars segment, Dr. Reddy’s Laboratories has introduced monoclonal antibodies and recombinant proteins targeting conditions such as rheumatoid arthritis and oncology indications. Additionally, its CRAMS division partners with global pharmaceutical firms to provide end‐to‐end drug discovery, development and manufacturing solutions.

Dr. Reddy’s serves markets across North America, Europe, Latin America, Russia & the Commonwealth of Independent States (CIS), and its home market of India. The company operates a network of research and development centers and manufacturing facilities in India, the United States, Europe and Mexico, adhering to international quality standards set by regulators such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Since its founding, leadership at Dr. Reddy’s Laboratories has steered the firm toward global expansion and innovation. The late Dr. Anji Reddy laid the foundation for a research‐driven culture, and the current executive team, led by Chairman Satish Reddy and Vice Chairman & Chief Executive Officer G.V. Prasad, continues to focus on strategic partnerships, pipeline growth and broadening access to affordable therapies worldwide.

Key Stats

• Today's Range: $13.45 to $13.63
• 50-Day Range: $12.45 to $14.22
• 52-Week Range: $12.19 to $16.17
• Volume: 1.48 million shs
• Average Volume: 2.27 million shs
• Market Capitalization: $11.30 billion
• P/E Ratio: 23.34
• Dividend Yield: 0.52%
• Price Target: $16.90
• Consensus Rating: Hold

Dr. Reddy's Laboratories Stock Analysis - MarketRank™

Dr. Reddy's Laboratories scored higher than 60% of companies evaluated by MarketBeat, and ranked 376th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Dr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

Upside Potential

Dr. Reddy's Laboratories has a consensus price target of $16.90, representing about 24.6% upside from its current price of $13.57.

Amount of Analyst Coverage

Dr. Reddy's Laboratories has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 16.98%

Earnings Growth

Earnings for Dr. Reddy's Laboratories are expected to grow by 16.98% in the coming year, from $0.53 to $0.62 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dr. Reddy's Laboratories is 23.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.17.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dr. Reddy's Laboratories is 23.39, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.51.

Price to Earnings Growth Ratio

Dr. Reddy's Laboratories has a PEG Ratio of 1.90. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Dr. Reddy's Laboratories has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.47% of the float of Dr. Reddy's Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Dr. Reddy's Laboratories has a short interest ratio ("days to cover") of 5.68.

Change versus previous month

Short interest in Dr. Reddy's Laboratories has recently increased by 28.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Dr. Reddy's Laboratories has a dividend yield of 0.52%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Dr. Reddy's Laboratories does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Dr. Reddy's Laboratories is 12.07%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 11.29% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Dr. Reddy's Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.

Percentage Held by Institutions

3.85% of the stock of Dr. Reddy's Laboratories is held by institutions.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/28/2026
• Next Earnings (Estimated): 7/22/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:RDY
• CIK: 1135951
• Web: www.drreddys.com
• Phone: 914049002900
• Fax: 91-40-4900-2999
• Employees: 27,811
• Year Founded: 1984

Price Target and Rating

• Average Price Target for Dr. Reddy's Laboratories: $16.90
• High Price Target: $16.90
• Low Price Target: $16.90
• Potential Upside/Downside: +24.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.58
• Trailing P/E Ratio: 23.34
• Forward P/E Ratio: 25.54
• P/E Growth: 1.9
• Net Income: $484.20 million
• Net Margins: 12.90%
• Pretax Margin: 16.32%
• Return on Equity: 12.16%
• Return on Assets: 8.12%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 1.80
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: $3.58 billion
• Price / Sales: 3.16
• Cash Flow: $0.85 per share
• Price / Cash Flow: 15.94
• Book Value: $5.15 per share
• Price / Book: 2.63

Miscellaneous

• Outstanding Shares: 834,650,000
• Free Float: 817,955,000
• Market Cap: $11.30 billion
• Optionable: Optionable
• Beta: 0.27